This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.
The DrugRisk Resource Center is the Web’s largest source for information on drug and medical device warnings, side effects and legal news. Visit http://www.DrugRisk.com
Orlando, FL (PRWEB) January 05, 2013
The prescription drug resource center DrugRisk.com has added new information to its already comprehensive database for the blood thinner Pradaxa, after an Australian health advisory questioned whether the drug was safe enough for the government to supply it to citizens.
“DrugRisk’s goal is to improve patient safety through education with the latest drug warnings, recalls, studies and litigation news. Although most people never hear about drug warnings from other countries, these can be just as important as those in the U.S.,” explained DrugRisk representative Ryan Mayer.
Last month, Australia’s Pharmaceutical Benefits Advisory Committee (PBAC) warned that they may withdraw recommendations that the government continue to furnish prescriptions of Pradaxa.*
The Committee noted concerns that, while Pradaxa may have health and financial benefits over other anticoagulants, it may be prescribed for patients and at dosages not tested in clinical trials.
In the United States, experts disagree about the safety of Pradaxa bleeding risks. Last month the FDA updated warnings to say the drug carries the same risks as warfarin.** However, the New York Times also reported doctors’ concerns that Pradaxa led all medications for adverse reports and currently has no antidote for internal bleeding.***
Most common among the adverse reports were 6497 gastrointestinal side effects, 4910 gastrointestinal hemorrhages (bleeding) and 2941 central nervous system or cranial hemorrhaging problems. There were also 842 deaths attributed to the drug.****
Since September, the number of patients filing a Pradaxa lawsuit over internal bleeding has risen 50%.***** The cases have now been moved to a special federal court in Illinois, formally known as MDL No. 2385, IN RE: Pradaxa Product Liability Litigation, Southern District of Illinois.
Anyone affected by internal bleeding after Pradaxa use is urged to speak with a lawyer about their legal options as soon as possible. Due to the specialized nature of federal drug injury cases, the Drug Risk Resource Center only recommends lawyers who are already handling Pradaxa lawsuits.
For more information on the research, side effects and litigation news related to Pradaxa and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.
For the original version on PRWeb visit: http://www.prweb.com/releases/prwebpradaxa-internal/bleedings-risks/prweb10290093.htm